Trial Profile

Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab With Pembrolizumab) in Combination With Concurrent Chemoradiotherapy Followed by MK-7684A Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III NSCLC

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 31 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Durvalumab (Primary) ; Etoposide (Primary) ; Paclitaxel (Primary) ; Pembrolizumab+vibostolimab (Primary) ; Pemetrexed (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; Registrational
Acronyms KEYVIBE-006
Sponsors Merck Sharp & Dohme

28 Mar 2025 Planned End Date changed from 4 Sep 2029 to 19 Aug 2026.
28 Mar 2025 Planned primary completion date changed from 1 Sep 2028 to 19 Aug 2026.
16 Dec 2024 Status changed from recruiting to discontinued, according to a Merck & Co media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com